AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05060900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament Reconstruction with Allograft Ligament
Description: Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
Study NCT06257290 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: at Day 1 - date of patient inclusion at time of VTE diagnosis
Study NCT06257290 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: at 6 months (in the patient follow-up)
Study NCT06589596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-58067
Description: Planned doses administered on specified days per protocol.
Study NCT05327699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
Study NCT05327699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
Study NCT05163951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: trabeculectomy
Study NCT05163951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPI+GSL+GT
Description: Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
Study NCT05323864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
Study NCT05323864 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hypoxia
Description: Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
Study NCT06367452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate + sodium bicarbonate + magaldrate + simeticone
Description: Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
Study NCT05372666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard white bread
Description: Bread to be consumed within 10 minutes after 10h fasting
Study NCT05372666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental white bread
Description: Bread to be consumed within 10 minutes after 10h fasting
Study NCT05372666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting
Study NCT05372666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental High-fiber bread
Description: Bread to be consumed within 10 minutes after 10h fasting
Study NCT05872178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omegia® Softgel -B
Description: How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
Study NCT05872178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omegia® Softgel -A
Description: How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
Study NCT05452226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation (NMES)
Description: Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
Study NCT06222749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Description: 24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
Study NCT06222749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo administration
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Study NCT05436002 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: With Cross-linked Hyaluronic Acid
Description: Without Cross-linked Hyaluronic Acid
Study NCT05436002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: With Cross-linked Hyaluronic Acid
Description: Without Cross-linked Hyaluronic Acid
Study NCT04661878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
Study NCT04661878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Resources
Description: The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
Study NCT04661878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Resources
Description: The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
Study NCT04661878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring and habit formation
Description: The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
Study NCT04661878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting and action planning
Description: The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
Study NCT05866497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical periodontal measurements
Description: Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop
Study NCT05866497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAVI measurements
Description: Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately.
Study NCT06234163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned intervention
Description: Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition.
Study NCT05087134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Description: 11C-Choline were injected into the patients before the PET/CT scans
Study NCT05352386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary computed tomography angiography (CCTA)
Description: Participants undergo coronary computed tomography angiography (CCTA)
Study NCT06041061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
Study NCT06041061 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Study NCT06772337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital cardiac rehabilitation
Description: Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
Study NCT06772337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Treatment
Description: Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Out-of-hospital cardiac rehabilitation: Receiving conventional treatment and secondary prevention drugs recommended by current guidelines, nutritional diet and lifestyle guidance, and establishing a WeChat group as a postoperative follow-up contact method.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
Study NCT05232890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Datterino tomato purée from hydroponic technology
Description: Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
Study NCT05232890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Datterino tomato puree from conventional cultivation
Description: Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
Study NCT05753800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTORUS
Description: Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
Study NCT05567341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
Study NCT05567341 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-control
Description: A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
Study NCT05427656 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] TRACK
Description: We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.
Study NCT05427656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Arterial Input Function
Description: The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
Study NCT05141864 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acmella oleracea gel
Description: Study group will use Acmella oleracea gel during the digital rectal examination.
Study NCT05141864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2 % Topical Cream
Description: Control group will use lidocaine 2% gel during the digital rectal examination.
Study NCT05141864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound gel
Description: Control group will use ultrasound gel during the digital rectal examination.
Study NCT05681208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week.
Study NCT05261464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol tartrate
Description: Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study NCT05261464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study NCT05261464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study NCT06367400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Sleep Questionnaire
Description: Questionnaire with 22 questions of symptoms of OSDB
Study NCT06177600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers
Description: Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked.
Study NCT06177600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers
Description: Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked.
Study NCT06066541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scorecard
Description: Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score.
Study NCT06066541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scorecard
Description: Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score.
Study NCT06066541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms
Description: Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).
Study NCT06066541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger effects
Description: Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.
Study NCT06066541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing fluency
Description: Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring.
Study NCT06116409 — intervention group
Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacaine was used for postoperative analgesia block.
Study NCT05839613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
Description: Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
Study NCT06127498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray
Description: Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.